InteliSwab test With less than one minute of “hands-on time,” the InteliSwab test is as simple as “Swab, Swirl, and...
Innovative series to highlight Jushi’s leading operational footprint, national expansion plans, and M&A strategy BOCA RATON, Fla., Jan. 31, 2022...
BOTHELL, Wash., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on...
Primary and key secondary endpoints from the double-blind placebo-controlled 969-patient MAESTRO-NAFLD-1 safety study were achieved and demonstrate that resmetirom: Was...
Synopsis of 2021 Achievements and Key Activities for 2022CALGARY, Alberta, Jan. 31, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX"...
Preliminary top line data anticipated throughout 2022HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage...
Late-breaker presentation to include new clinical data from Cohort 1 in the Imagine-1 clinical trial for GM1 gangliosidosis, Friday, February...
Enrollment in 48-week Phase 2 clinical trial expected to begin in Q1 2022GAITHERSBURG, Md., Jan. 31, 2022 (GLOBE NEWSWIRE) --...
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing...
CAMBRIDGE, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc. (NASDAQ: SGTX), a biotechnology company that seeks to develop...
TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA),...
ACTON, Mass., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay”, “the Company”) a late-stage, pre-revenue diagnostics...
- VRDN-002 incorporates clinically validated half-life extension technology to support development as a low volume subcutaneous injection -- Company expects...
BOSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Akouos, Inc. (“Akouos”) (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing...
LA JOLLA, Calif., Jan. 31, 2022 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market...
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated May 11, 2021...
R1 received 100% ranking and was named one of the Best Places to Work for LGBTQ+ EqualityMURRAY, Utah, Jan. 31,...
RESEARCH TRIANGLE PARK, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company...
New data support Phase 3 development of Nyxol alone as a durable single eye drop for the potential treatment of...
Results show a strong first fiscal year, with $5.5 million in cash and continued growth from operationsVancouver, British Columbia--(Newsfile Corp....
